Recent NRBO News
- NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June • PR Newswire (US) • 04/30/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 04/17/2024 12:05:00 PM
- NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 04/01/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/28/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 03/13/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer • PR Newswire (US) • 03/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:14 PM
- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/29/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:52:22 PM
- NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference • PR Newswire (US) • 02/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:15 PM
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/01/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:23 PM
- NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 01/18/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:45:11 PM
- NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement • PR Newswire (US) • 01/09/2024 01:30:00 PM
- NeuroBo to Participate in Industry and Investor Conferences in January • PR Newswire (US) • 01/02/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 02:00:14 PM
- NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 12/28/2023 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 02:03:45 PM
- NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split • PR Newswire (US) • 12/19/2023 01:43:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 02:20:48 PM
- NeuroBo to Participate in Investor Conferences in December • PR Newswire (US) • 12/01/2023 01:31:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:29:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM